DiaMedica Therapeutics Inc

NASDAQ DMAC

Download Data

DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio 3 year CAGR for the quarter ending March 31, 2024: -5.98%

DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio 3 year CAGR is -5.98% for the quarter ending March 31, 2024, a -11.22% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2023 was -3.75, a -77.95% change year over year.
  • DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2022 was -2.11, a 32.68% change year over year.
  • DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2021 was -3.13, a 29.29% change year over year.
  • DiaMedica Therapeutics Inc Retained Earnings To Equity Ratio for the quarter ending March 31, 2020 was -4.43, a -25.20% change year over year.
NASDAQ: DMAC

DiaMedica Therapeutics Inc

CEO Mr. Dietrich John Pauls MBA
IPO Date Jan. 4, 2008
Location United States
Headquarters Two Carlson Parkway, Minneapolis, MN, United States, 55447
Employees 18
Sector Healthcare
Industry Biotechnology
Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Similar companies

MIST

Milestone Pharmaceuticals Inc

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email